A Phase IB Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 [semaxanib] and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck

Trial Profile

A Phase IB Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 [semaxanib] and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2010

At a glance

  • Drugs Semaxanib (Primary) ; Paclitaxel
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jun 2007 Updated from NCT record dated 4 Jun 2007.
    • 11 Jan 2007 Status change
    • 08 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top